Daxor Reports 45% Revenue Growth, FDA Clearance for Next-Gen Analyzer, and Reduced Operating Loss in 2025
DXR sits 69% above its 52-week low of $6.8 on elevated volume (14× avg).
Summary
Daxor Corporation reported strong fiscal year 2025 results, highlighted by a 45% increase in operating revenue and a significant reduction in its operating loss, moving closer to break-even. The company also emphasized the August 2025 FDA 510(k) clearance for its next-generation Blood Volume Analyzer, a product developed under contract with the U.S. Department of Defense, which is expected to drive future growth. Net Asset Value per share rose to $9.07, reflecting an increase in total net assets. These positive developments, coupled with a recently closed $9 million registered direct offering in January 2026, signal a strategic realignment and strong commercial momentum for Daxor's core blood volume measurement business.
At the time of this announcement, DXR was trading at $11.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.3M. The 52-week trading range was $6.80 to $14.76. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.